111, Inc. Sponsored ADR (NASDAQ:YI) Short Interest Down 78.6% in August

111, Inc. Sponsored ADR (NASDAQ:YI) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 900 shares, a decline of 78.6% from the August 15th total of 4,200 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On 111

An institutional investor recently bought a new position in 111 stock. Deuterium Capital Management LLC acquired a new position in 111, Inc. Sponsored ADR (NASDAQ:YI) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $81,000. Deuterium Capital Management LLC owned approximately 0.12% of 111 as of its most recent SEC filing. 21.32% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 111 in a research note on Saturday, August 30th.

111 Stock Performance

111 stock opened at $5.92 on Friday. The company has a 50 day moving average price of $6.87 and a 200-day moving average price of $7.68. 111 has a fifty-two week low of $4.14 and a fifty-two week high of $11.90. The company has a market capitalization of $51.17 million, a PE ratio of -9.25 and a beta of 0.46.

111 (NASDAQ:YI) last posted its quarterly earnings results on Thursday, June 19th. The company reported ($0.20) earnings per share for the quarter. The firm had revenue of $486.35 million for the quarter.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.